Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 21:14:1291922.
doi: 10.3389/fphar.2023.1291922. eCollection 2023.

From heart failure and kidney dysfunction to cardiorenal syndrome: TMAO may be a bridge

Jialun Zhang #  1 , Peining Zhu #  2 , Siyu Li  1 , Yufei Gao  2 , Yue Xing  1
Affiliations
Review

From heart failure and kidney dysfunction to cardiorenal syndrome: TMAO may be a bridge

Jialun Zhang et al. Front Pharmacol. .

Abstract

The study of trimethylamine oxide (TMAO), a metabolite of gut microbiota, and heart failure and chronic kidney disease has made preliminary achievements and been summarized by many researchers, but its research in the field of cardiorenal syndrome is just beginning. TMAO is derived from the trimethylamine (TMA) that is produced by the gut microbiota after consumption of carnitine and choline and is then transformed by flavin-containing monooxygenase (FMO) in the liver. Numerous research results have shown that TMAO not only participates in the pathophysiological progression of heart and renal diseases but also significantly affects outcomes in chronic heart failure (CHF) and chronic kidney disease (CKD), besides influencing the general health of populations. Elevated circulating TMAO levels are associated with adverse cardiovascular events such as HF, myocardial infarction, and stroke, patients with CKD have a poor prognosis as well. However, no study has confirmed an association between TMAO and cardiorenal syndrome (CRS). As a syndrome in which heart and kidney diseases intersect, CRS is often overlooked by clinicians. Here, we summarize the research on TMAO in HF and kidney disease and review the existing biomarkers of CRS. At the same time, we introduced the relationship between exercise and gut microbiota, and appropriately explored the possible mechanisms by which exercise affects gut microbiota. Finally, we discuss whether TMAO can serve as a biomarker of CRS, with the aim of providing new strategies for the detection, prognostic, and treatment evaluation of CRS.

Keywords: cardiorenal syndrome; chronic kidney disease; heart failure; trimethylamine; trimethylamine oxide.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Production and metabolism of TMAO (By Figdraw).
See this image and copyright information in PMC

References

    1. Al-Obaide M. A. I., Singh R., Datta P., Rewers-Felkins K. A., Salguero M. V., Al-Obaidi I., et al. (2017). Gut microbiota-dependent trimethylamine-N-oxide and serum biomarkers in patients with T2DM and advanced CKD. J. Clin. Med. 6 (9), 86. 10.3390/jcm6090086 - DOI - PMC - PubMed
    1. Alvelos M., Pimentel R., Pinho E., Gomes A., Lourenço P., Teles M. J., et al. (2011). Neutrophil gelatinase-associated lipocalin in the diagnosis of type 1 cardio-renal syndrome in the general ward. Clin. J. Am. Soc. Nephrol. 6 (3), 476–481. 10.2215/CJN.06140710 - DOI - PMC - PubMed
    1. Al-Waiz M., Ayesh R., Mitchell S. C., Idle J. R., Smith R. L. (1987). Disclosure of the metabolic retroversion of trimethylamine N-oxide in humans: a pharmacogenetic approach. Clin. Pharmacol. Ther. 42 (6), 608–612. 10.1038/clpt.1987.207 - DOI - PubMed
    1. Anderson K. M., Ferranti E. P., Alagha E. C., Mykityshyn E., French C. E., Reilly C. M. (2022). The heart and gut relationship: a systematic review of the evaluation of the microbiome and trimethylamine-N-oxide (TMAO) in heart failure. Heart Fail Rev. 27 (6), 2223–2249. 10.1007/s10741-022-10254-6 - DOI - PubMed
    1. Bain M. A., Faull R., Fornasini G., Milne R. W., Evans A. M. (2006). Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. Nephrol. Dial. Transpl. 21 (5), 1300–1304. 10.1093/ndt/gfk056 - DOI - PubMed